LHRH


Also found in: Medical, Acronyms, Wikipedia.

LHRH

abbr.
luteinizing hormone-releasing hormone
Translations

LHRH

abbr luteinizing hormone-releasing hormone. V. hormone.
References in periodicals archive ?
While the costs for LHRH therapy differ depending on drug and formulation, on average the monthly costs of these medications are approximately $300-400.
Increased final height in precocious puberty after long-term treatment with LHRH agonists: the National Institutes of Health experience.
LHRH agonistlerine kronik maruziyet, LHRHreseptorlerinin down regulasyonu ile sonuclanir, LH ve FSH salgilanmasi ve dolayisiyla testosteron uretimi baskilanir.
Antihormonal agents like danazol, bromocriptine, tamoxifen and LHRH analogs have been used, but most of them are steroid-based with significant side effects.
Furuya, Benzimidazole Derivatives as Novel Non-Peptide Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists.
The patient did not respond to LHRH test (basal FSH was 0.01 mIU/ml and LH was 0.11 mIU/ml; peak FSH was 0.01 mIU/ml and peak LH was 0.12 mIU/ml).
Intravenous pdC1INH 1000 U twice a week was continued and during that period she received LHRH injection four times.
Some studies have shown that cotreatment with luteinizing hormone-releasing hormone (LHRH) agonists and continuation of tamoxifen resolves ovarian hyperstimulation and that LHRH agonists are given by monthly injections for 3 or 6 months [4, 5].
Also in humans, a clinical combination of melatonin and the LHRH analogue triptorelin was tested in metastatic prostate cancer patients with promising results.
Neurons within the hypothalamus produce and secrete releasing hormones, such as corticotropin-releasing factor (CRF), luteinizing hormone--releasing hormone (LHRH), thyrotropin-releasing hormone (TRH), and growth hormone--releasing hormone (GRH), as well as inhibiting hormones, such as somatostatin and dopamine, directly into the blood vessel connecting the hypothalamus with the pituitary gland (i.e., the hypothalamic--hypophyseal portal vein).
Very few studies have been published on the efficacy of CPA or other androgen-depleting medications like medroxyprogesterone acetate (MPA) or the GnRH analogues [also known as GnRH agonists or luteinising hormone-releasing hormone (LHRH) agonists] like leuprolide, triptorelin and goserelin in the treatment of hypersexuality and sexually inappropriate behaviour, and high-quality evidence in favour of their use is lacking.